Beneficial Ownership Report · SCHEDULE 13G/A
Freenome, Inc.
FRNMNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Freenome, Inc.
- Company CIK
- 0002017526
- Street
- Genesis Marina, 3300 Marina Blvd
- City
- Brisbane
- State / country code
- CA
- Postal code
- 94005
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.0001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Perceptive Advisors LLC
- Citizenship / organization
- DE
- Reporting person type
- IA
- Group designation
- b
- Aggregate amount owned
- 12,606,053
- Percent of class
- 11.3
- Sole voting power
- 0
- Shared voting power
- 12,606,053
- Sole dispositive power
- 0
- Shared dispositive power
- 12,606,053
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Joseph Edelman
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- b
- Aggregate amount owned
- 12,606,053
- Percent of class
- 11.3
- Sole voting power
- 0
- Shared voting power
- 12,606,053
- Sole dispositive power
- 0
- Shared dispositive power
- 12,606,053
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Perceptive Life Sciences Master Fund, Ltd.
- Citizenship / organization
- E9
- Reporting person type
- CO
- Group designation
- b
- Aggregate amount owned
- 12,518,597
- Percent of class
- 11.2
- Sole voting power
- 0
- Shared voting power
- 12,518,597
- Sole dispositive power
- 0
- Shared dispositive power
- 12,518,597
- Aggregate excludes certain shares
- N
Reporting person 4
- Name
- C2 Life Sciences LLC
- Citizenship / organization
- NY
- Reporting person type
- OO
- Group designation
- b
- Aggregate amount owned
- 87,456
- Percent of class
- 0.1
- Sole voting power
- 0
- Shared voting power
- 87,456
- Sole dispositive power
- 0
- Shared dispositive power
- 87,456
- Aggregate excludes certain shares
- N
Item 1
Issuer
Freenome, Inc.
Principal executive office address
Genesis Marina, 3300 Marina Blvd, Brisbane, California, 94005
Item 2
Citizenship
Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation. C2 is a New York limited liability company.
Filing person
The names of the persons filing this report (collectively, the "Reporting Persons") with respect to the Common Stock, par value $0.0001 per share (the "Common Stock") of Freenome, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") (iv) C2 Life Sciences LLC ("C2")
Principal business or residence address
The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
Item 3
Not applicable indication
Y
Item 4
Percent of class
Perceptive Advisors: 11.3% Mr. Edelman: 11.3% Master Fund: 11.2% C2: 0.1%
Amount beneficially owned
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 111,500,956 shares of Common Stock outstanding as of November 9, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds 12,518,597 shares of Common Stock, and C2 directly holds 87,456 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and C2, and may be deemed to beneficially own shares held by the Master Fund and C2. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the shares held by the Master Fund and C2.
Sole voting power
Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 C2: 0
Shared voting power
Perceptive Advisors: 12,606,053 Mr. Edelman: 12,606,053 Master Fund: 12,518,597 C2: 87,456
Sole dispositive power
Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 C2: 0
Shared dispositive power
Perceptive Advisors: 12,606,053 Mr. Edelman: 12,606,053 Master Fund: 12,518,597 C2: 87,456
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- Perceptive Advisors LLC
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman, Managing Member
- Date
- 11/16/2026
Signature 2
- Reporting person
- Joseph Edelman
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman
- Date
- 11/16/2026
Signature 3
- Reporting person
- Perceptive Life Sciences Master Fund, Ltd.
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman, Managing Member
- Date
- 11/16/2026
Signature 4
- Reporting person
- C2 Life Sciences LLC
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman, Managing Member
- Date
- 11/16/2026
Company context
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com.
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by ADAR1 Capital Management, LLC regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Holocene Advisors, LP regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by One Fin Capital Management LP regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by RTW INVESTMENTS, LP regarding Freenome, Inc.Nov 16, 2026